In the past week, LRMR stock has gone down by -2.70%, with a monthly gain of 7.01% and a quarterly surge of 1.93%. The volatility ratio for the week is 9.52%, and the volatility levels for the last 30 days are 7.89% for Larimar Therapeutics Inc The simple moving average for the past 20 days is -1.74% for LRMR’s stock, with a -2.16% simple moving average for the past 200 days.
Is It Worth Investing in Larimar Therapeutics Inc (NASDAQ: LRMR) Right Now?
LRMR has 36-month beta value of 0.95. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LRMR is 37.33M, and currently, short sellers hold a 7.30% ratio of that float. The average trading volume of LRMR on November 14, 2024 was 647.93K shares.
LRMR) stock’s latest price update
Larimar Therapeutics Inc (NASDAQ: LRMR) has experienced a decline in its stock price by -12.17 compared to its previous closing price of 9.04. However, the company has seen a fall of -2.70% in its stock price over the last five trading days. zacks.com reported 2024-11-11 that Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
Analysts’ Opinion of LRMR
Many brokerage firms have already submitted their reports for LRMR stocks, with Oppenheimer repeating the rating for LRMR by listing it as a “Outperform.” The predicted price for LRMR in the upcoming period, according to Oppenheimer is $26 based on the research report published on October 16, 2024 of the current year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see LRMR reach a price target of $22. The rating they have provided for LRMR stocks is “Outperform” according to the report published on October 03rd, 2024.
H.C. Wainwright gave a rating of “Buy” to LRMR, setting the target price at $15 in the report published on October 02nd of the current year.
LRMR Trading at 6.83% from the 50-Day Moving Average
After a stumble in the market that brought LRMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.96% of loss for the given period.
Volatility was left at 7.89%, however, over the last 30 days, the volatility rate increased by 9.52%, as shares surge +2.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.19% upper at present.
During the last 5 trading sessions, LRMR fell by -2.70%, which changed the moving average for the period of 200-days by +35.73% in comparison to the 20-day moving average, which settled at $8.08. In addition, Larimar Therapeutics Inc saw 74.51% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LRMR starting from Hamilton Thomas Edward, who purchase 57,208 shares at the price of $8.74 back on Feb 16 ’24. After this action, Hamilton Thomas Edward now owns 564,798 shares of Larimar Therapeutics Inc, valued at $499,998 using the latest closing price.
Flynn James E, the Director of Larimar Therapeutics Inc, purchase 4,290,617 shares at $8.74 during a trade that took place back on Feb 16 ’24, which means that Flynn James E is holding 6,151,406 shares at $37,499,993 based on the most recent closing price.
Stock Fundamentals for LRMR
The total capital return value is set at -0.36. Equity return is now at value -44.50, with -40.11 for asset returns.
Based on Larimar Therapeutics Inc (LRMR), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -56.81.
Currently, EBITDA for the company is -41.45 million with net debt to EBITDA at 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.10.
Conclusion
To put it simply, Larimar Therapeutics Inc (LRMR) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
